Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma

Ophélie Champion, Sophie Maiga, Christelle Dousset, Agnès Aubry, Céline Bellanger, François Guillonneau, Jose Antonio Moreno, Ohyun Kwon, Philippe Moreau, David Chiron, Catherine Pellat-Deceunynck, Cyrille Touzeau, Patricia Gomez-Bougie

Blood (2024) 144 (Supplement 1): 3282.

https://doi.org/10.1182/blood-2024-194462

Published: 2024

Journal Articles

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Blood (2024) 143 (13): 1242–1258.

https://doi.org/10.1182/blood.2023021581

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

Romane Durand, Domitille Costes-Tertrais, Geraldine Descamps, Christelle Dousset, Sophie Maïga, Jean-Baptiste Alberge, Elise Douillard, Jennifer Derrien, Celine Bellanger, David Chiron, Stephane Minvielle, Cyrille Touzeau, Philippe Moreau, Martine Amiot, Patricia Gomez-Bougie, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck

Blood (2022) 140 (Supplement 1): 4198–4199.

https://doi.org/10.1182/blood-2022-155862

Published: 2022

Journal Articles

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Patricia Gomez-Bougie, Sophie Maiga, Benoît Tessoulin, Jessie Bourcier, Antoine Bonnet, Manuel S. Rodriguez, Steven Le Gouill, Cyrille Touzeau, Philippe Moreau, Catherine Pellat-Deceunynck, Martine Amiot

Blood (2018) 132 (25): 2656–2669.

https://doi.org/10.1182/blood-2018-03-836718

Published: 2018

Includes: Supplemental data

Journal Articles

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Jessie Bourcier, MD, Antoine Bonnet, MD, Géraldine Descamps, PhD, Carolane Seiller, Cyrille Touzeau, MD PhD, Philippe Moreau, Catherine Pellat-Deceunynck, PhD, Martine Amiot, PhD

Blood (2018) 132 (Supplement 1): 953.

https://doi.org/10.1182/blood-2018-99-109987

Published: 2018

Journal Articles

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Antoine Bonnet, MD, Jessie Bourcier, MD, Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Philippe Moreau, MDPhD, Steven Le Gouill, MDPhD, Catherine Pellat-Deceunynck, PhD, Cyrille Touzeau, MD PhD, Martine Amiot, PhD

Blood (2017) 130 (Supplement 1): 4383.

https://doi.org/10.1182/blood.V130.Suppl_1.4383.4383

Published: 2017

Journal Articles

Combination Of 2-Deoxy-D-Glucose With ABT-199 Efficiently Kills All Molecular Subgroups Of Myeloma Cells

Maxime Halliez, Sophie Maïga, Cyrille Touzeau, MD, Patricia Gomez-Bougie, PhD, Steven Le Gouill, MD, PhD, Marie-Christine Bene, PharmSciD, PhD, Philippe Moreau, MD, Catherine Pellat-Deceunynck, PhD, Martine Amiot, PhD

Blood (2013) 122 (21): 1921.

https://doi.org/10.1182/blood.V122.21.1921.1921

Published: 2013

Journal Articles

The Cap-Translation Inhibitor 4EGI-1 Induces Apoptosis in Multiple Myeloma Through Noxa Induction and Synergizes with ABT-737

Géraldine Descamps, PhD, Patricia Gomez-Bougie, PhD, Didier Bouscary, MD, PhD, Philippe Moreau, MD, Régis Bataille, PhD, Catherine Pellat-Deceunynck, PhD, Martine Amiot, PhD

Blood (2011) 118 (21): 1832.

https://doi.org/10.1182/blood.V118.21.1832.1832

Published: 2011

Journal Articles

TP53 Is Not Involved in the Apoptosis Induced by RITA

Sylvanie Surget, PhD, in, training, Vincent Normant, Carole Brosseau, PhD, Sophie Maiga, Patricia Gomez-Bougie, Géraldine Descamps, Steven Le Gouill, MD, PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2011) 118 (21): 1848.

https://doi.org/10.1182/blood.V118.21.1848.1848

Published: 2011

Journal Articles

ABT-737 is highly effective against molecular subgroups of multiple myeloma

Linda Bodet, Patricia Gomez-Bougie, Cyrille Touzeau, Christelle Dousset, Géraldine Descamps, Sophie Maïga, Hervé Avet-Loiseau, Régis Bataille, Philippe Moreau, Steven Le Gouill, Catherine Pellat-Deceunynck, Martine Amiot

Blood (2011) 118 (14): 3901–3910.

https://doi.org/10.1182/blood-2010-11-317438

Published: 2011

Includes: Supplemental data

Journal Articles

Rational for the Use of a Targeted-Therapy Using ABT-737 In Mantle-Cell Lymphoma

Cyrille Touzeau, Christelle Dousset, Lynda Bodet, Stephanie Bonnaud, Patricia Gomez-Bougie, Thomas Gastinne, Soraya Wuilleme, Anne Moreau, Philippe Moreau, Catherine Pellat-Deceunynck, PhD, Martine Amiot, Steven Le Gouill

Blood (2010) 116 (21): 770.

https://doi.org/10.1182/blood.V116.21.770.770

Published: 2010

Journal Articles

TP53 Positively Regulates Cell Death through TRAILR2 (DR5) but Negatively through TRAILR1 (DR4) In Myeloma Cells

Sylvanie Surget, PhD, in, training, Patricia Gomez-Bougie, David Chiron, PhD, in, training, Robin Humphreys, PhD, Philippe Moreau, Steven Le Gouill, Jean-Luc Harousseau, Regis Bataille, MD, PhD, Martine Amiot, Catherine Pellat-Deceunynck, PhD

Blood (2010) 116 (21): 136.

https://doi.org/10.1182/blood.V116.21.136.136

Published: 2010

Journal Articles

High Bcl-2/Mcl-1 Gene Expression Ratio Identifies Molecular Sub-Groups of Multiple Myeloma Patients Extremely Sensitive to ABT-737

Linda Bodet, Catherine Pellat-Deceunynck, PhD, Patricia Gomez-Bougie, PhD, Christelle Dousset, Cyrille Touzeau, Steven Le Gouill, MD, PhD, Hervé Avet-Loiseau, MD, PhD, Regis Bataille, MD, PhD, Martine Amiot, PhD

Blood (2010) 116 (21): 4061.

https://doi.org/10.1182/blood.V116.21.4061.4061

Published: 2010

Journal Articles

Agonist Anti-TRAILR1 Human Mab, Hgs-ETR1, Induces Myeloma Cell Death Mainly through the Intrinsic Pathway of Apoptosis.

Emmanuelle Ménoret, Sylvanie Surget, Patricia Gomez-Bougie, Régis Bataille, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2008) 112 (11): 1713.

https://doi.org/10.1182/blood.V112.11.1713.1713

Published: 2008

Journal Articles

The Pan-Bcl-2 Inhibitor GX15-O70 Induces Apoptosis in Human Myeloma Cells by Noxa Induction and Strongly Enhances Melphalan, Bortezomib or TRAIL-R1 Antibody Apoptotic Effect.

Patricia Gomez-Bougie, MD, PhD, Sophie Maïga, BSc, Catherine Pellat-Deceunynck, PhD, Sandrine Jouan, MSc, Regis Bataille, MD PhD, Martine Amiot, PhD

Blood (2006) 108 (11): 3476.

https://doi.org/10.1182/blood.V108.11.3476.3476

Published: 2006

Journal Articles

A Humanized Anti-IGF-1R Monoclonal Antibody (AVE1642) Synergizes with Bortezomib To Induce Apoptosis in CD45neg Myeloma Cells.

Geraldine Descamps, PhD, Soraya Wuilleme-Toumi, MD, Patricia Gomez-Bougie, MD, PhD, Corinne Venot, PhD, Friedhelm Bladt Bladt, PhD, Regis Bataille, MD, PhD, Martine Amiot, PhD

Blood (2006) 108 (11): 845.

https://doi.org/10.1182/blood.V108.11.845.845

Published: 2006

Journal Articles

Mcl-1L cleavage is involved in TRAIL-R1– and TRAIL-R2–mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells

Emmanuelle Menoret, Patricia Gomez-Bougie, Alexandrine Geffroy-Luseau, Sylvanne Daniels, Philippe Moreau, Steven Le Gouill, Jean-Luc Harousseau, Regis Bataille, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2006) 108 (4): 1346–1352.

https://doi.org/10.1182/blood-2005-12-007971

Published: 2006

Journal Articles

The Complex Mcl-1/Bim Regulates the Sensitivity of Human Myeloma Cells to Melphalan.

Patricia Gomez-Bougie, MD, Lisa Oliver, PhD, Emmanuelle Menoret, Steven Le Gouill, MD, Régis Bataille, PHD, MD, Martine Amiot, PHD

Blood (2005) 106 (11): 357.

https://doi.org/10.1182/blood.V106.11.357.357

Published: 2005

Journal Articles

TRAILR Triggering by Human Antibodies Induces Apoptosis through an Early Cleavage of Mcl-1 and Caspase 3 in Myeloma Cells.

Catherine Pellat-Deceunynck, PhD, Patricia Gomez-Bougie, MD, Sylvanne Daniels, Alexandrine Geffroy-Luseau, Regis Bataille, MD, PhD, Martine Amiot, PhD

Blood (2005) 106 (11): 3397.

https://doi.org/10.1182/blood.V106.11.3397.3397

Published: 2005

Journal Articles

Mcl-1 Is Overexpressed in Multiple Myeloma and Correlates with Disease Severity.

Soraya Wuilleme-Toumi, MD, Nelly Robillard, PhD, Patricia Gomez-Bougie, MD, Philippe Moreau, MD, Steven Le Gouill, MD, Herve Avet-Loiseau, MD, PhD, Jean-Luc Harousseau, MD, Martine Amiot, PhD, Regis Bataille, MD, PhD

Blood (2004) 104 (11): 1419.

https://doi.org/10.1182/blood.V104.11.1419.1419

Published: 2004

NARROW

Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Combination Of 2-Deoxy-D-Glucose With ABT-199 Efficiently Kills All Molecular Subgroups Of Myeloma Cells

The Cap-Translation Inhibitor 4EGI-1 Induces Apoptosis in Multiple Myeloma Through Noxa Induction and Synergizes with ABT-737

TP53 Is Not Involved in the Apoptosis Induced by RITA

ABT-737 is highly effective against molecular subgroups of multiple myeloma

Rational for the Use of a Targeted-Therapy Using ABT-737 In Mantle-Cell Lymphoma

TP53 Positively Regulates Cell Death through TRAILR2 (DR5) but Negatively through TRAILR1 (DR4) In Myeloma Cells

High Bcl-2/Mcl-1 Gene Expression Ratio Identifies Molecular Sub-Groups of Multiple Myeloma Patients Extremely Sensitive to ABT-737

Agonist Anti-TRAILR1 Human Mab, Hgs-ETR1, Induces Myeloma Cell Death Mainly through the Intrinsic Pathway of Apoptosis.

The Pan-Bcl-2 Inhibitor GX15-O70 Induces Apoptosis in Human Myeloma Cells by Noxa Induction and Strongly Enhances Melphalan, Bortezomib or TRAIL-R1 Antibody Apoptotic Effect.

A Humanized Anti-IGF-1R Monoclonal Antibody (AVE1642) Synergizes with Bortezomib To Induce Apoptosis in CD45neg Myeloma Cells.

Mcl-1L cleavage is involved in TRAIL-R1– and TRAIL-R2–mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells

The Complex Mcl-1/Bim Regulates the Sensitivity of Human Myeloma Cells to Melphalan.

TRAILR Triggering by Human Antibodies Induces Apoptosis through an Early Cleavage of Mcl-1 and Caspase 3 in Myeloma Cells.

Mcl-1 Is Overexpressed in Multiple Myeloma and Correlates with Disease Severity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only